PDS Biotech Announces PDS0202 Universal Influenza Vaccine Preclinical Data

PDS Biotech Corporation, a clinical-stage immunotherapy company developing novel infectious disease vaccines and cancer therapies on the basis of its proprietary InfectimuneTM and Versamune® T-cell activating technologies.

Because there are so many different strains of flu, a new seasonal flu vaccine is generally created to defend against the strains that are projected to be the most common during the upcoming flu season. As a result, the existing vaccinations’ protective effectiveness varies greatly from one season to the next. PDS Biotech is working on a new generation of flu vaccinations that might give long-lasting and wide protection against numerous flu strains.

We believe that if a universal flu vaccine is developed successfully, it will be unnecessary to manufacture vaccines to guard against the expected mutations each year. Flu causes 3 to 5 million illnesses and 290,000 to 650,000 fatalities per year, according to the World Health Organization.PDS0202 combines PDS Biotech unique InfectimuneTM technology with Dr. Ted Ross’s proprietary COBRA (Computationally Optimized Broadly Reactive Antigens) technology. The COBRA antigens have been licensed by PPDS Biotech to the University of Georgia.On the NIAID-sponsored preclinical work, PDS Biotech cooperated with Dr. Jerold Woodward of the University of Kentucky College of Medicine and Dr. Ted Ross of the University of Georgia.

In the studies, PDS0202 was found to stimulate the generation of broadly neutralising influenza-specific antibodies, flu-specific CD8 (killing) and CD4 (helper) T-cells, and long-lasting memory T-cells. This well-understood and powerful immune response to COBRA antigens implies a high likelihood of widespread and long-term protection against a variety of influenza strains.